Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 4Head & Neck 3Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 1

Conditions

Stomach Neoplasms 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Pancreatic Neoplasms 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × SHR-1701 × Gastrointestinal × Clear all
NCT05671822 2026-02-12

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2 Recruiting
258 enrolled
Gastrointestinal

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
351 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05149807 2025-08-20

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2/3 Terminated
81 enrolled
Gastrointestinal

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

NCT04624217 2024-01-11

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Completed
56 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡